Introduction

Presenters from the 2023 SGO annual meeting shared their insights on the treatment of patients with gynecologic cancers. Ursula A. Machelonus MD discussed final overall survival data from the Phase 3 Nova trial of Neuraparib in patients with recurrent ovarian cancer. Dr. Cara Matthews MD discussed seven-year overall survival data for newly diagnosed, brachimutated, advanced ovarian cancer who received maintenance ollaparib. Ramese N. Eskander, MD, discussed findings from the Phase3 NRG-GY018 trial of Pembrolysmab plus paxletaxil and carboclatin in patients with Stage 3, 4A